"This clearance of ProLectin-M into the clinic is very important given that this is the first of a number of indications that we intend to pursue to treat large unmet medical needs with our Glycovirology technology," said Dr
This class of galectin inhibitors is groundbreaking because peer reviewed clinical trial results suggest many patients can become PCR negative in as little as 3 days. Even though we are seeing a resurgence of COVID-19 and its newest variants, BA.2.86 and EG.5, we view our COVID-19 trials as case studies designed to showcase the potential of the galectin antagonist as a broad-spectrum antiviral drug."
About ProLectin-M
ProLectin-M is an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells. In recent clinical trials the drug achieved a 100% responders rate of negative PCR tests by day 7. In 3 days, the drug achieved an 88% responders rate of negative PCR tests. The treated population experienced no viral rebounds during the 14-day observation period. The company is preparing for a phase 3 clinical trial in order to seek regulatory approval.
About
More information can be found at www.bioxytraninc.com
Media Contact
Company
Contact Person: Investor Relations
Email: stonefelix962@gmail.com
Phone: 617.510.2539
Country:
Website: https://www.bioxytraninc.com/
Source: www.abnewswire.com
.
(C) 2023 M2 COMMUNICATIONS, source